One-Dose malaria cure for kids? new trial begins

NCT ID NCT07052162

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a single dose of tafenoquine in 30 children in Papua New Guinea who have vivax malaria. The goal is to see how the drug moves through the body and if it is safe. Vivax malaria can come back because it hides in the liver, and this drug aims to clear it completely.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

tafenoquine

What this could lead to

If successful, this could provide a simpler, single-dose treatment option for vivax malaria in children, helping to prevent relapses.

What could go wrong

This is a small, early-phase study focused on drug levels and safety, not yet proving effectiveness. Side effects like low hemoglobin are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PHARMACOKINETICS OF TAFENOQUINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Plasmodium vivax malaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Alexishafen Health Centre

    RECRUITING

    Madang, Madang Province, MP511, Papua New Guinea

    Contact Phone: •••-•••-•••• Email: •••••@•••••